Fresh concerns about data-center funding weighed down Oracle’s stock on Wednesday, but the selloff is looking overdone to some on Wall Street. Christine Ji is a reporter covering Big Tech.

Larry Ellison’s Oracle is stumbling into the end of the year with its shares taking a beating. The tech firm’s stock has plummeted 30% so far this quarter, CNBC noted Friday. Only four trading days ...

At least 14 states and Washington, DC, are reporting high or very high flu activity. The dominant flu strain, a version of influenza A (H3N2) called subclade K, has multiple mutations that make it ...

Larry Ellison is putting his over $250 billion fortune on the line to bankroll his son’s Hollywood power play. The 81-year-old Oracle founder has agreed to personally guarantee up to $40.4 billion to ...

What To Know: While the stock rallied Monday on reports that a consortium led by Oracle, Silver Lake and MGX agreed to acquire a significant stake in TikTok's U.S. operations, sentiment appears to ...

The Food and Drug Administration on Monday approved a pill version of Wegovy, Novo Nordisk’s blockbuster weight loss drug. The Wegovy pill, as it’s called, is first oral version of a GLP-1 drug that ...

The agency greenlit an oral version of the obesity drug Wegovy. By Dani Blum The Food and Drug Administration on Monday approved a pill version of the weight-loss injectable drug Wegovy, offering ...

The US Food and Drug Administration on Monday approved a daily pill version of Novo Nordisk’s weight-loss drug Wegovy, introducing a new option for how patients can take medicines in a class of drugs ...

Oracle stock has been struggling as investors worry about the growing debt to fund its AI buildout. However, an acceleration in Oracle's growth in the next fiscal year could alleviate those concerns.